Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Y. Hu, E. M. Lewandowski, H. Tan, R. T. Morgan, X. Zhang, L. M. Jacobs, S. G. Butler, M. V. Mongora, J. S. Choy, Y. Chen, J. Wang
The study identifies SARS-CoV-2 Mpro mutations associated with nirmatrelvir resistance from clinical isolates.
bioRxiv · Jun 28, 2022Pharmacology & Toxicology